VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

Conclusion The combination of vorinostat + bortezomib is active in multiple myeloma patients refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (clinicaltrials.gov: NCT00773838). Teaser This study was designed to determine efficacy and tolerability of vorinostat in combination with bortezomib in multiple myeloma patients. Patients received 21-day cycles of bortezomib + vorinostat. Objective response rate was 11.3% (95% CI: 6.6%, 17.7%) and median duration of response of 211 days (64-550). Vorinostat + bortezomib is active in multiple myeloma patients refractory to novel treatment modalities.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research